Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma

Molecular Cancer Therapeutics

Volumn 6, Issue 1, 2007, Pages 203-212

  Stutchbury, Tamantha K ^a   Al Ejeh, Fares ^a,e   Stillfried, Gillian E ^a   Croucher, David R ^a   Andrews, John ^b   Irving, David ^c   Links, Matthew ^d   Ranson, Marie ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b JLA Bioprocess Consulting   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e HANSON INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH 213; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE; ANTINEOPLASTIC AGENT; BISMUTH; RADIOISOTOPE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ARTICLE; BODY POSTURE; BREAST CARCINOMA; CANCER INVASION; CANCER SURVIVAL; CELL INTERACTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE MODEL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ENDOCYTOSIS; ENZYME INHIBITION; FIBROBLAST; GROWTH RATE; HUMAN; HUMAN CELL; IMMOBILIZATION; MAXIMUM TOLERATED DOSE; METASTASIS POTENTIAL; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SKIN DISCOLORATION; SPECIES DIFFERENCE; TOXICOLOGY; TUMOR GROWTH; WEIGHT REDUCTION; ANIMAL; BLOOD CELL COUNT; BREAST TUMOR; CELL DEATH; CHEMISTRY; DRUG ADMINISTRATION; DRUG EFFECT; DRUG SCREENING; ENZYME SPECIFICITY; FEMALE; METABOLISM; PATHOLOGY; PROTEIN BINDING; REPRODUCIBILITY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BISMUTH; BLOOD CELL COUNT; BREAST NEOPLASMS; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MICE; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEIN BINDING; RADIOISOTOPES; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY; TREATMENT OUTCOME; URINARY PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33846804080     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0264     Document Type: Article

References (36)

1. Schmitt M, Wilhelm O, Reuning U, et al. The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinol Proteol 2000; 14:114-32.
2. Ranson M, Andronicos NM. Plasminogen binding and cancer: promises and pitfalls. Front Biosci 2003;8:s294-304.
3. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004;10:39-49.
4. Romer J, Nielsen BS, Ploug M. The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des 2004;10:2359-76.
5. Ertongur S, Lang S, Mack B, et al. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer 2004;110:815-24.
6. Almholt K, Lund LR, Rygaard J, et al. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer 2005;113:525-32.
7. Kruithof EKO, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type-2. Blood 1995;86:4007-24.
8. Al-Ejeh F, Croucher D, Ranson M. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines. Exp Cell Res 2004;297:259-71.
9. Silverman GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001;276:33293-6.
10. Kjoller L. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol Chem 2002;383:5-19.
11. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005;5:591-602.
12. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-7.
13. Dano K, Behrendt N, Hoyer-Hansen G, et al. Plasminogen activation and cancer. Thromb Haemost 2005;93:676-81.
14. Liu S, Aaronson H, Mitola DJ, Leppla SH, Bugge TH. Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc Natl Acad Sci U S A 2003; 100:657-62.
15. Robinson MK, Weiner LM, Adams GP. Improving monoclonal anti-bodies for cancer therapy. Drug Dev Res 2004;61:172-87.
16. Ranson M, Tian Z, Andronicos NM, Rizvi S, Allen BJ. In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (α-PAI-2) on human breast cancer cells. Breast Cancer Res Treat 2002;71:149-59.
17. 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model. Br J Cancer 2002;86:1197-203.
18. 213Bi-labelled-plasminogen activator inhibitor type 2. Br J Cancer 2003;88:944-50.
19. Hang MTN, Ranson M, Saunders DN, et al. Pharmacokinetics and biodistribution of recombinant human plasminogen activator inhibitor type 2 (PAI-2) in control and tumour xenograft-bearing mice. Fibrinol Proteol 1998; 12:145-54.
20. Croucher D, Saunders DN, Ranson M. The urokinase/PAI-2 complex: A new high affinity ligand for the endocytosis receptor LRP. J Biol Chem 2006;281:10206-13.
21. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with α-emitting nuclides. Eur J Nucl Med 1998;25:1341-51.
22. Ranson M, Andronicos NM, O'Mullane MJ, Baker MS. Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins. Br J Cancer 1998;77:1586-97.
23. Andronicos NM, Ranson M. The topology of plasminogen binding and activation on the surface of human breast cancer cells. Br J Cancer 2001;85:909-16.
24. Williams JW, Morrison JF. The kinetics of reversible tight-binding inhibition. Methods Enzymol 1979;63:437-67.
25. Allen BJ, Raja C, Rizvi S, et al. Intralesional targeted α therapy for metastatic melanoma. Cancer Biol Ther 2005;4:1318-24.
26. Perry MC. Chemotherapy source book. Philadelphia: Lippincott, Williams and Wilkins; 2001.
27. Jessani N, Humphrey M, McDonald WH, et al. Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. Proc Natl Acad Sci U S A 2004;101:13756-61.
28. Allen BJ, Rizvi S, Li Y, Tian Z, Ranson M. In vitro and preclinical targeted α therapy for melanoma, breast, prostate and colorectal cancers. Crit Rev Oncol Hematol 2001;39:139-46.
29. Solberg H, Ploug M, Hoyer-Hansen G, Nielsen BS, Lund LR. The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J Histochem Cytochern 2001;49:237-46.
30. Jurcic JG, Larson SM, Sgouros G, et al. Targeted α particle immunotherapy for myeloid leukemia. Blood 2002; 100: 1233-9.
31. McDevitt MR, Barendswaard E, Ma D, et al. An α-particle emitting antibody ([213Bi]J591) for radioirnmunotherapy of prostate cancer. Cancer Res 2000; 60:6095-100.
32. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {α}-particle therapy. J Nucl Med 2005;46 Suppl 1:199-204S.
33. Hall EJ. The bystander effect. Health Phys 2003;85:31-5.
34. Belyakov OV, Malcolmson AM, Folkard M, Prise KM, Michael BD. Direct evidence for a bystander effect of ionizing radiation in primary human fibroblasts. Br J Cancer 2001;84:674-9.
35. Shao C, Furusawa Y, Kobayashi Y, Funayama T, Wada S. Bystander effect induced by counted high-LET particles in confluent human fibroblasts: a mechanistic study. FASEB J 2003; 17:1422-7.
36. Chabner BA, Roberts TG, Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 2005; 5:65-72.